07:00 Mon 23 Aug 2021
Destiny Pharma PLC - Notice of Interim Results
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Notice of Interim Results and Investor Presentation
The presentation is open to analysts and all existing and potential new shareholders. Questions can be submitted pre-event via the Investor Meet Company Dashboard up until
Investors can sign up to Investor Meet Company for free, and add to meet Destiny Pharma plc via:
https://www.investormeetcompany.com/destiny-pharma-plc/register-investor
Investors who already follow Destiny Pharma plc on the Investor Meet Company platform will automatically be invited.
-END-
For further information, please contact:
Destiny Pharma plc
+44 (0)1273 704 440
Optimum Strategic Communications
Mary Clark /
DestinyPharma@optimumcomms.com
+44 (0) 208 078 4357
finnCap Ltd (Nominated Advisor Joint Broker)
+44 (0) 207 220 0500
WG Partners (Joint Broker)
+44 (0) 203 705 9330
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.
For further information, please visit www.destinypharma.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE